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ABSTRACT
Women with past gestational diabetes mellitus (GDM) 
are at risk of subsequent type 2 diabetes and adverse 
cardiovascular events. Digital and telemedicine 
interventions targeting weight loss and reductions in body 
mass index (BMI) may help reduce risk for women with 
GDM. The aim was to compare the effectiveness of digital 
or telemedicine intervention with usual care. Randomized 
controlled trials (RCTs) were identified in Embase, Medline, 
CINAHL, PsycINFO and the Cochrane Library. Included 
trials recruited women with prior GDM but without pre- 
existing diabetes, and tested a digital or telemedicine 
intervention with or without an in- person component. 
Data extraction was carried out independently by two 
authors. The search yielded 898 citations. Eighteen articles 
reporting 15 trials were included, of which 8 tested digital 
interventions. Reported outcomes included weight, BMI, 
fasting plasma glucose and waist circumference. None of 
the included trials reported type 2 diabetes incidence or 
cardiovascular risk. Data were pooled using a random- 
effects model. The point estimate favored the intervention 
but was non- significant for both BMI (−0.90 kg/m2, 95% 
CI −1.89 to 0.09; p=0.08) and weight (−1.83 kg, 95% 
CI −4.08 to 0.42, p=0.11). Trials evaluating digital and 
telemedicine interventions identified clinically relevant, but 
non- significant improvements in BMI and weight compared 
with control. No trials assessed type 2 diabetes occurrence 
as an outcome. More well- designed RCTs with adequate 
power and long- term follow- up are needed to identify 
the impact of these interventions on type 2 diabetes 
occurrence.
BACKGROUND
Gestational diabetes (GDM) is defined as 
hyperglycemia first identified in pregnancy, 
usually during the second or third trimester. 
Screening for GDM is offered to women with 
one or more risk factors (eg, body mass index 
(BMI) >30 kg/m2) and diagnoses typically 
made with abnormal values on an oral glucose 
tolerance test. GDM affects an estimated 
5%–20% of pregnancies.1 Hyperglycemia 
generally resolves within weeks of delivery but 
it can predict subsequent diabetes mellitus.
Women living with GDM have a sevenfold 
increased risk for subsequent type 2 diabetes2 
and they are twice as likely to develop hyper-
tension and have increased risk for ischemic 
heart disease.3 During the 5 years following 
delivery, type 2 diabetes incidence can rise 
sharply before plateauing around a decade 
later.4 The temporal lag between GDM 
and type 2 diabetes may offer a therapeutic 
window of intervention and the National 
Institutefor Health and Care Excellence 
(NICE) recommends dietician referral and 
lifestyle modification.5
In general, interventions promoting weight 
loss and exercise in people at risk of type 2 
diabetes significantly reduce incidence of 
type 2 diabetes, and can reduce markers of 
cardiovascular health.6–8 However, women 
with GDM can find it difficult to make life-
style changes.9 For instance, busy routines, 
low self- efficacy and poor social support have 
been identified as barriers to change.10 11 
Women with and without GDM have similar 
weight retention and reduced physical activity 
in the postpartum period,12 but following 
GDM there are additional health risks.
The role of digital interventions in deliv-
ering healthcare have recently been examined 
by WHO.13 These interventions can be deliv-
ered in various ways including automated text 
messages, web- platforms and online consul-
tations. They are used in several contexts 
and can provide multiple services including 
educational resources, goal- setting and 
remote self- monitoring. Intervening using 
digital interventions has been conducted 
in the areas of smoking cessation,14 hyper-
tension and weight loss.15 In comparison, 
telemedicine refers to delivery of remote 
health, involving telephone consultations and 
videoconferences, particularly useful where 
distance can prevent face- to- face contact.
Both digital and telemedicine interven-
tions can facilitate lifestyle change by supple-
menting or replacing face- to- face contact, 
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potentially overcoming barriers. To date, prototype 
applications have been viewed positively by women with 
GDM.16 However, inconsistent findings mean it is unclear 
if they are genuinely superior to standard care.17 18 
Previous systematic reviews focusing on GDM have either 
not addressed digital interventions or they have focused 
on management during pregnancy rather than after.2 19 20 
Therefore, we addressed this gap in evidence by focusing 
on the impact of digital and telemedicine interventions 
(with or without in- person contact) on weight and BMI 




The protocol for this systematic review was prospec-
tively registered (PROSPERO registration number: 
CRD42019145051). This review is reported according to 
the Preferred Reporting Items for Systematic Review and 
Meta- Analysis (PRISMA) statement.21
Eligibility criteria
Participants: trials included women aged ≥18 years with a 
prior GDM diagnosis, but those recruiting women with 
pre- existing diabetes were ineligible. Trials recruiting 
women during the GDM affected pregnancy were eligible 
for inclusion. Interventions: digital interventions included 
websites and text messages. Telemedicine interventions 
not including any digital component, such as interven-
tions only involving telephone calls, were treated as 
distinct from digital interventions. Trials without any 
digital or telemedicine component were excluded. For 
the purposes of this review, trials reporting interventions 
including both in- person and digital or telemedicine 
components were eligible for inclusion. Comparisons: trials 
comparing digital or telemedicine interventions with a 
usual care comparator were included. Outcomes: trials 
with BMI or weight reported in a 3–6 months time frame 
post partum were included in the meta- analysis. Trials 
that reported these outcomes outside this time frame or 
other secondary outcomes of interest for lifestyle inter-
ventions were retained for the systematic review quali-
tative summary. Outcomes must have been measured at 
least 6 weeks post partum. Study design: only randomized 
controlled trials (RCTs) were eligible for inclusion.
Information sources
The search strategy was applied to Embase, MEDLINE, 
CINAHL, PsycINFO and The Cochrane Library from the 
inception of each database to February 17, 2020. The 
full, electronic search strategy used to identify trials from 
the Embase database is listed in online supplemental 
table S1. No language or date restriction was applied. 
The coverage and date of search is presented in online 
supplemental table S2.
Study selection
Titles and abstracts of all citations identified by the 
search were screened by JH and MEW independently 
using Rayyan, a web and mobile application for system-
atic reviews.22 Disagreements were discussed and esca-
lated for resolution to a third reviewer (AJF). Full- text 
articles were screened for eligibility with any discrepan-
cies resolved through discussion. References cited in the 
manuscripts of the included trials were also checked for 
additional RCTs not identified in the database search.
Data collection process
JH and MEW extracted data independently using a 
custom Cochrane Collaboration data extraction form. 
The form was initially piloted for two trials to check it 
collected all of the appropriate fields. Any disagreements 
were discussed and resolved with AF. In the event missing 
data were recorded, we did not contact study authors.
Data items
Data were extracted for title, authors, publication date, 
setting (country and context), study design, study dura-
tion, GDM diagnostic criteria, participant characteristics 
(including age and ethnicity) and sample size, as well 
as details of the intervention and comparator condi-
tions. The primary outcome of interest was weight and 
BMI at least 6 weeks post partum. Secondary outcomes 
included type 2 diabetes incidence, cardiovascular risk, 
waist circumference, fasting plasma glucose (FPG), oral 
glucose tolerance test (OGTT), physical activity and 
dietary behaviors.
Risk of bias in individual studies
Risk of bias was assessed by the first and second author 
using the Cochrane Collaboration’s risk of bias tool. 
The included trials were judged as being either at low 
risk, high risk or with an unclear level of risk. Disagree-
ments were resolved with AF. Cluster RCTs were reported 
separately.
Synthesis of results
If more than two trials reported both baseline and 
follow- up values, findings were pooled using a random- 
effects model using RevMan V.5.3 software. Missing 
SD values for mean change were derived using equa-
tions recommended by Cochrane (Cochrane Hand-
book: Chapter 16.1.3.2). Where possible, SD values 
were derived from 95% CI. When trials reported data at 
multiple follow- up timepoints, the earliest timepoint was 
chosen for pooling to align with the other trials. Summary 
measures were reported along with 95% CI. Heteroge-
neity of trials were reported using the I2 statistic; 0%–40% 
was considered not significantly important, while ≥75% 
deemed to have significant heterogeneity.
RESULTS
A total of 941 citations were identified from the data-
base searches and from checking the reference lists of 
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included papers (figure 1 and online supplemental table 
S2). Thirty- nine full- text articles were retrieved. Eighteen 
citations were eligible for inclusion, reporting results 
of 15 studies (3 citations were conference proceeding 
reports of subsequently published work and 2 citations 
reported results from the same study).
Trial characteristics
General study characteristics are presented in table 1. 
Sample size ranged from 2823 to 248024 people and 
five trials were reported as pilot studies.25–29 Trial dura-
tions ranged from 12 weeks25 30 to 12 months.23 Of the 
trials that reported the country in which the research 
was done, Australia and New Zealand (n=6), the USA 
(n=4), Canada (n=1) and Europe (n=2) were listed. The 
majority of trials were in the hospital setting with eight 
trials recruiting during pregnancy, six recruiting post 
partum and one recruiting women in late pregnancy or 
shortly after birth.31 A variety of criteria were also used 
to determine eligibility for including women with GDM 
(online supplemental table S3).
Intervention characteristics
Nine trials reported digital interventions and seven 
reported telemedicine interventions, using telephone 
calls. A full description of the various trials is provided 
in online supplemental table S4. One trial assigned 
controls to a waiting list to the nutritional program.30 
Usual care included a clinic- based educational class,32 
an educational DVD33 and printed materials being most 
frequent (n=8) (table 1).
Risk of bias
Results of the risk of bias assessment for all included 
studies are presented in figure 2. One trial was judged 
to have high risk of bias for random sequence genera-
tion because randomization was assigned by week of 
attendance at postpartum OGTT, rather at the level of 
the individual.33 Four trials either blinded personnel 
carrying out outcome assessment or analysts undertaking 
statistical analyses.
Primary outcome
Reported outcomes of each trial are listed in online 
supplemental table S5.
Of the 13 trials reporting weight as an outcome, 5 
revealed significant differences.23 26 30 32 33 One trial 
reported a significant difference favoring the interven-
tion (p=0.002), but was excluded from the meta- analysis 
by reporting median and IQR.30 A mixture of self- 
report and clinic- measured weight were reported. Data 
from six trials were pooled where the data were avail-
able and where outcomes were reported at 3–6 months 
(figure 3A).23 25 26 29 31 33 The point estimate favored inter-
vention but overall was non- significant (−1.83 kg; 95% CI 
−4.08 to 0.42; p=0.11), nor within either subgroup 
analyses. The I2 statistic was 78%, indicative of high 
heterogeneity.
Figure 1 Preferred Reporting Items for Systematic Review and Meta- Analysis flow of the selection process.
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Seven trials reported a change in BMI. Four trials 
found significant differences between intervention and 
control.23 26 29 31 33 A mixture of self- report and clinic- 
measured BMI was calculated. Available data from five 
trials were pooled for meta- analysis where outcomes were 
reported across 3–6 months (figure 3B).23 26 29 31 33 Four of 
the trials included a digital element, with both subgroup 
analyses remaining significant. Overall, the point estimate 
favored the intervention but overall was non- significant 
(−0.90 kg/m2; 95% CI −1.89 to 0.09; p=0.08) and the I2 
statistic was 77%.
Secondary outcomes
Key outcomes are reported in online supplemental table 
S6. Several trials did not report prespecified outcomes 
of interest in this review. One trial reported psycholog-
ical determinants of behavior change,34 and one trial 
reported weight change in a form that could not be quan-
titatively extracted.35 One trial36 did not report FPG and 
instead only reported post partum 2 hours OGTT. Find-
ings revealed no significant difference between 3 months 
postpartum results between the two groups (p=0.25). 
One trial32 reported blood pressure, a marker of adverse 
cardiovascular risk when raised, but found no significant 
difference between groups at follow- up. No included 
trials reported occurrence of type 2 diabetes or cardio-
vascular events. No trials reported economic analysis of 
the interventions.
Fasting plasma glucose
Only one trial reported a significant effect, but favoring 
control.30 Inconsistency in reporting was noted with one 
trial32 reporting baseline and follow- up data for the inter-
vention group only, and another trial omitting baseline 
values.28 Three other trials reporting FPG revealed non- 
significant differences.25 29 33
Figure 2 Risk of bias assessment.
Figure 3 Forest plots for (A) weight and (B) body mass index (BMI).
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Waist circumference
Two digital trials reported significant improvements in 
favor of the intervention.30 33 Two trials reported non- 
significant effects favoring intervention,26 29 whereas two 
trials reported greater reduction for controls.25 31
Physical activity
Eight trials measured levels of physical activity24–30 35 and 
only one of these trials used activity monitors to measure 
device- based physical activity.25 Insufficient reporting 
prevented data pooling. No significant differences were 
reported.
Diet
Ten trials reported dietary behaviors.23 24 26–28 30 31 33–35 
Four of these trials23 26 27 35 reported significant effects 
favoring the intervention; notably reductions in calorie 
intake,23 dietary fat intake,27 daily total intake35 and carbo-
hydrate intake.26 One study identified barriers to healthy 
eating and reported a significant reduction in barriers in 
response to the intervention.34 Only one trial28 explicitly 
reported interview- led measurement (ie, dietician- led, 
rather than self- report) to assist with outcome measure-
ment at baseline. Inconsistent use of dietary behavior 
outcomes prevented data pooling.
Cluster RCT
One trial used a cluster design.24 In this trial, significantly 
more women achieved postpartum weight goals in the 
intervention group over 12 months (OR 1.28, 95% CI 
1.10 to 1.47) compared with the usual care group.24 
Mean weight change between groups was significant 
at 6 months (p=0.01) but not at 12 months (p=0.12). 
Mean change in vigorous physical activity was significant 
at 6 months (15.4 min/week, 95% CI 4.9 to 25.8) but 
moderate or total activity/week was not.
Dropout from studies
The rate of dropout from the included trials is reported 
in table 2. Withdrawal ranged from 6.7% to 52.5% and 
averaged 24.8% in the intervention group. Control group 
dropout, in comparison, ranged from 7.7% to 60% and 
averaged 23.5% across reporting trials. Studies investi-
gating a digital intervention averaged a higher dropout 
rate than the telemedicine trials (30.7% vs 14.6%, respec-
tively). Two trials26 32 did not report rates of dropout by 
group, however did report a rate of 5.2% (n=6/116) 
and 5.3% (n=2/38), respectively, across the sample. Two 
trials did not report trial drop- out rates.35 When trials 
did report reasons for dropout, they ranged from being 
too busy, work- related reasons, subsequent diagnoses of 
diabetes, subsequent pregnancy, spontaneous abortion 
or being lost to follow- up. Eight of the trials reported 




We aimed to investigate the effect of digital and tele-
medicine interventions on weight and BMI following 
GDM. Our meta- analysis identified a statistically non- 
significant reduction in BMI and weight and the CIs of 
the impact of the interventions on weight included a 
clinically important impact. Reducing weight lowers type 
2 diabetes incidence,37 with every 1 kg lost reducing risk 
of diabetes by 16%.38 Interventions could potentially be 
cost- effective, but no economic analyses were reported 
beyond unit costs.
There is international recognition of digital platforms 
as being potentially helpful in the management and 
treatment of disease and risk.13 National guidelines are 
currently being developed by NICE on the use of digital 
and mobile health interventions to support behavior 
change.39 The fast pace of development of emerging tech-
nologies requires that assessments of impact are updated 
regularly to remain relevant. These novel digital inter-
ventions may modify current clinical practice, potentially 
reducing the reliance on face- to- face consultation.40
In the review, we grouped interventions into either 
digital or telemedicine. While both may help supple-
ment or reduce sole reliance on face- to- face consulta-
tion, which can be overwhelming for new mothers,41 the 
mode of their delivery differs. Telephone conversation, 
while not replicating face- to- face interactions, can be 
more convenient. In contrast, the delivery of a digital 
intervention may be different from that of a face- to- 
face consultation, for example, an interactive website or 
multiple platforms with data collection can reduce phys-
ical contact with health professionals and provide educa-
tional information with websites accessible at any time 
and from any location.23 30–32 Many of the trials iden-
tified in this review used multiple methods of delivery 
(including a combination of in- person and digital or 
Table 2 Rates of dropout across the included studies 
reported by group allocation (where available)
Intervention group Control group
Digital
  Borgen et al36 34/115 (29.6%) 41/123 (33.3%)
  Carolan- Olan32 N/A N/A
  Cheung et al28 21/40 (52.5%) 12/20 (60%)
  Holmes et al33 9/29 (31%) 6/31 (19.4%)
  Kim et al29 2/21 (9.5%) 5/28 (17.9%)
  McManus et al31 44% 42%
  Nicklas23 6/36 (16.7%) 3/39 (7.7%)
  Peacock et al30 5/16 (31.3%) 3/15 (20%)
Telemedicine
  Ferrara et al27 19/96 (19.8%) 10/101 (9.9%)
  Ferrara et al24 216/1187 (18.2%) 207/1293 (16%)
  Hedderson35 N/A N/A
  Jelsma et al34 4/29 (13.8%) 5/30 (16.7%)
  McIntyre et al25 1/15 (6.7%) 2/13 (15.4%)
  Reinhardt et al26 N/A N/A
N/A, not applicable.
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telemedicine) leading to heterogenous interventions 
and ‘key ingredients’ not being easily identified. In addi-
tion, we report that the dropout rates from the interven-
tions comprising a telemedicine component averaging a 
slightly lower dropout rate (14.6%) compared with the 
studies exploring an intervention with a digital compo-
nent (30.7%). Future studies should direct careful 
consideration toward minimizing dropout and ensure 
clear reporting on drop out by group allocation with 
reasons when collected.
No trials reported on the long- term outcomes of GDM, 
which are challenging to measure, particularly in the 
context of device trials. A systematic review led by Goveia 
et al42 identified that lifestyle interventions can signifi-
cantly reduce diabetes incidence by 25% using data from 
eight trials, with trials offering the intervention within 
6 months post partum most effective. In our review, we 
focused on proxy indicators of health status including 
BMI and weight, which can provide evidence for inter-
mediate outcomes known to predict long- term adverse 
consequences. Goveia et al demonstrated moderate 
reductions in weight (−1.07 kg), BMI (−0.94 kg/m2) and 
waist circumference (−0.98 cm) following participation in 
a lifestyle intervention, but did not distinguish between 
trials using digital/non- digital delivery.42 Other reviews 
in the area of GDM have looked at reducing diabetes risk 
showing low recruitment rates and possible contributions 
to postpartum weight loss and improved dietary behav-
iors.43 Reviews specifically focusing on telemedicine- 
based interventions have shown that monitoring glucose 
levels can result in significant reductions in HbA1c19 and 
GDM services can be streamlined using telemedicine 
without compromising maternal or fetal outcomes.20 Our 
review adds to the literature that digital/telemedicine 
interventions have not shown significant improvements 
in weight or BMI 3–6 months post partum. However, it 
does not rule out clinically meaningful changes in weight 
loss from participation in a digital/telemedicine inter-
vention compared with usual care.
The effect size observed for weight loss and change 
in BMI was not substantially different. Although the 
CIs for weight loss did not provide evidence of a statis-
tically significant effect, this does not exclude a clin-
ically important benefit. The trials included in the 
pooled estimates of impact on weight and BMI only 
differed by the additional inclusion of McIntyre et al in 
the BMI quantitative analysis. The extent of heteroge-
neity suggests a need for more consistent selection of 
outcome measures in trials. One additional trial noted 
during our systematic review but not included due to 
ineligibility revealed that outcomes can also focus on 
breastfeeding duration.44 Several of the studies were 
deemed to have an unclear level of risk of bias with 
one study33 deemed to be at high risk. This is a notable 
finding and suggests that future research studies should 
implement explicit transparent reporting on risk attri-
bution to selection bias, performance bias, detection 
bias and attrition bias.
Challenges and limitations
Reporting of both planned intervention fidelity and 
actual delivery of intervention was limited across all 
trials. Many trials commented on whether participants 
used the system, but details such as call duration were 
often missing. The search strategy was comprehensive 
and inclusive, which identified some studies that did 
not include outcomes of interest. This review reported 
outcomes according to PRISMA, but findings were limited 
by reporting and design of included trials. While find-
ings on behavior change are encouraging, there are chal-
lenges in interpreting self- report behavior. For example, 
in the instance where physical activity was reported, it 
was self- reported rather than device- based which raises 
concerns around social desirability bias. The methods 
used to collect weight and BMI were largely through clin-
ical measurement; however, a few trials did use self- report 
methods or a combination of self- report and clinical 
measurement.26 In one trial the method of collection was 
unclear.33 The digital and telemedicine field is rapidly 
advancing, meaning backward- looking review is required 
to evaluate possible beneficial impact from these inter-
ventions. However, lack of standardized reporting and 
timepoint of assessment presented a barrier to direct 
comparison between trials, and the search strategy did 
not identify any relevant trials addressing theories of 
behavior change. This suggests a need for promoting 
long- term behavior change with digital and telemedi-
cine interventions with long- term follow- up of clinical 
outcomes.
Summary
In summary, this systematic review demonstrated the 
point estimate of the effect of the intervention on weight 
and BMI has potential to be clinically relevant but was 
not statistically significant. Previous systematic reviews 
suggest telemedicine interventions can aid management 
of GDM during pregnancy, but do not conclude these 
interventions were superior to standard care.19 20 Find-
ings from the present review provide evidence that these 
interventions can positively impact important short- 
term outcomes following pregnancy. Large, adequately 
powered, multicentre trials of longer duration are needed 
to determine their impact on long- term outcomes (such 
as type 2 diabetes incidence). Economic evaluations 
should also be incorporated to establish whether the 
implementation of digital and telemedicine intervention 
are cost- effective.
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